Gastroenterologia Japonica

, Volume 27, Issue 4, pp 482–487 | Cite as

The effect of dopamine on rat gastric motility

  • Yoshi Nagahata
  • Tomoaki Urakawa
  • Hiromitsu Kuroda
  • Kenji Tomonaga
  • Hideki Idei
  • Naoto Kawakita
  • Kazuo Yoshizumi
  • Yoichi Saitoh
Alimentary Tract


The inhibitory mechanism of dopamine (DA) on rat gastric motility was investigated in association with DA receptors. Gastric movement was assessed according to the method of Jacoby et al and was expressed with the system of Ludwick et al. (1968). DA inhibited gastric movement in both the corpus and antrum in a dose-dependent manner. Domperidone, a specific antagonist of DA2 receptor, suppressed DA-induced inhibition of gastric movement in a dose-dependent manner. SCH23390, a specific antagonist of DA1 receptor did not affect DA-induced inhibition of gastric movement. LY171555, a specific agonist of DA2 receptor, inhibited gastric movement in both the corpus and antrum in a dose-dependent manner. SKF38393, a specific agonist of DA1 receptor, did not affect gastric movement. These results indicate that DA plays an important role in the inhibitory regulation of gastric motility, through DA2 receptor but not DA1 receptor.

Key words

gastric motility dopamine dopamine receptor 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Van Rooyen JM, Offermeier J. Peripheral dopamitjergic receptors. SA Med J 1981;59:329–332.Google Scholar
  2. 2.
    Bell C. Dopamine as a postganglionic autonomic neurotransmitter. Neuroscience 1982;7:1–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Sahyoun HA, Costall B, Naylor J. On the ability of domperidone to selectively inhibit catecholamine-induced relaxation of circular smooth muscle of guinea-pig stomach. J Pharm Pharmacol 1982;34:27–333.PubMedGoogle Scholar
  4. 4.
    Urakawa T, Nakamoto M, Kumagai K, et al. Inhibitory mecha nism of dopamine on rat gastric motility. Current Therapeutic Research 1987;42:1096–1108.Google Scholar
  5. 5.
    Jacoby HI, Bass P, Bennett DR. In vivo extraluminal contractile force transducer for gastrointestinal muscle. J Appl Physiol 19633;18:658–665.Google Scholar
  6. 6.
    Ludwick JR, Wiley JN, Bass P. Extraluminal contractile force and electrical activity of reversed canine duodenum. Gastroenterology 1968;54:41–51.PubMedGoogle Scholar
  7. 7.
    Kebabian JW. Multiple classes of dopamine receptors in mammalian central nervous system. Life Sci 1978;23:479–484.PubMedCrossRefGoogle Scholar
  8. 8.
    Yeh BK, McNay JL, Golderg LI. Antennation of dopamine renal and mesenteric vasodilation by haloperidol. J Pharmacol Exp Ther 1969;168:303–309.PubMedGoogle Scholar
  9. 9.
    Goldberg LI. Cardiovascular and renal actions of dopamine. Pharmacol Rev 1972;24:1–29.PubMedGoogle Scholar
  10. 10.
    Clark BJ, Menninger K. Peripheral dopamine receptors. Circ Res 1980;46(Suppl I):I59-I63.PubMedGoogle Scholar
  11. 11.
    Sowers JR, Stern N, Taylor IL. Evidence of dopaminergic modulation of pancreatic polypeptide secretion in man. Life Sci 1982;31:2971–2975.PubMedCrossRefGoogle Scholar
  12. 12.
    Ratten S, Goyal RK. Effect of dopamine on the esophageal smooth muscle in vivo. Gastroenterology 1976;70:377–381.Google Scholar
  13. 13.
    Bron B, Massih L. Domperidone: A drug with powerful action on the lower esophageal sphincter pressure. Digestion 1980;20:375–378.PubMedCrossRefGoogle Scholar
  14. 14.
    Kohli JD, Glock D, Goldberg LI. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery. Eur J Pharmacol 1983;89:137–141.PubMedGoogle Scholar
  15. 15.
    Nagahata Y, Urakawa T. Experimental studies on the role of dopamine in stress ulcer. Jpn J Gastroentrol 1986;83:1289–1297. (in Japanese)Google Scholar
  16. 16.
    Kumagai K, Nagahata Y, Urakawa T, et al. An experimental study of the action of dopamine in suppressing pentagastrin stimulated gastric acid secretion and its mechanism in rats. Jpn J Gastroenterol 1990;87:1636–1643. (in Japanese)Google Scholar
  17. 17.
    Azumi Y, Urakawa T, Nagahata Y, et al. An experimental study of the action of dopamine in increasing gastric mucosal blood flow and its mechanism. Jpn J Gastroenterol 1988;85:1360–1368. (in Japanese)Google Scholar
  18. 18.
    Nagahata Y, Urakawa T, Saitoh Y. Effect of dopamine on prostaglandin E2 content in gastric mucosa. Gastroenterol Jpn 1990;25:681–684.PubMedGoogle Scholar
  19. 19.
    Szabo S. Biology of disease. Pathogenesis of duodenal ulcer disease. Lab Invest 1984;51:121–147.PubMedGoogle Scholar
  20. 20.
    Nagahata Y, Urakawa T, Moritomo H, et al. Effects of dopamine on stress ulcer. Jpn J Gastroenterol 1990;87:1376–1382. (in Japanese)Google Scholar
  21. 21.
    Nagahata Y, Urakawa T, Itoh A, et al. Effects of dopamine on stress ulcer. Cytoprotection & Cytobiology 1989;6:139–144.Google Scholar
  22. 22.
    Beck K, Hovendal CP, Anderson D. Effect of dopamine on pentagastrin-stimulated gastric antral motility in dogs with gastric fistula. Scand J Gastroenterol 1982;17:103–107.Google Scholar
  23. 23.
    Beck K, Hovendal CP, Gottrup F, et al. Dopaminergic and Β-adrenergic effects on gastric antral motility. Scand J Gastroenterol 1984;19(Suppl 89):65–70.Google Scholar
  24. 24.
    Baudry M, Martres MP, Schwarz JC.3H-domperidone: A selective ligand for dopamine receptors. Maunyn-Schmied Arch Pharmacol 1979;308:231–237.CrossRefGoogle Scholar
  25. 25.
    Valenzuela JE, Lin DP. The effect of variations in intragastric pressure and gastric emptying of saline meal in humans. Scand J Gastroenterol 1982;17:293–296.PubMedCrossRefGoogle Scholar
  26. 26.
    Fujii K, Takasugi S, Toki N. Excitatory response of gastric movement by domperidone and the mechanism involved. Arzneim-Forsch Drug Res 1980;30:640–644.Google Scholar
  27. 27.
    Shuto K, Shiozaki S, Kojima T, et al. Effect of KW-5338 (domperidone) on gastric motility. J Pharm Dyn 1980;3:715–719.Google Scholar
  28. 28.
    Nakamoto M, Urakawa T, Saitoh Y Inhibitory mechanism of dopamine on rat gastric motility. Jpn J Gastroenterol 1987;84:653–660. (in Japanese)Google Scholar
  29. 29.
    Goldberg LI, Glock D, Kohli JD, et al. Separation of peripheral dopamine receptors by a selective DA2 antagonist, SCH23390. Hypertension 1984;6:25–30.Google Scholar
  30. 30.
    Hilditch A, Drew GM, Naylor RJ. SCH is a very potent and selective antagonist at vascular dopamine receptors. Eur J Pharmacol 1984;97:333–334.PubMedCrossRefGoogle Scholar
  31. 31.
    Hahn RA, McDonald BR, Martin MA. Antihypertensive activity of LY141865, a selective presynaptic dopamine receptor agonist. J Pharmacol Exp Ther 1983;224:206–214.PubMedGoogle Scholar
  32. 32.
    Hahn RA, Wardell JRJ. Renal vascular activity Sk&F38393 and dopamine in anesthetized dogs. J Cardiovasc Pharmacol 1980;2: 583–593.PubMedCrossRefGoogle Scholar
  33. 33.
    ArlËns EJ. Molecular Pharmacology vol 1, London and New York: Academic Press, 1964;l-466.Google Scholar

Copyright information

© The Japanese Society of Gastroenterology 1992

Authors and Affiliations

  • Yoshi Nagahata
    • 1
  • Tomoaki Urakawa
    • 2
  • Hiromitsu Kuroda
    • 1
  • Kenji Tomonaga
    • 1
  • Hideki Idei
    • 1
  • Naoto Kawakita
    • 1
  • Kazuo Yoshizumi
    • 1
  • Yoichi Saitoh
    • 1
  1. 1.First Department of SurgeryKobe University School of MedicineKobeJapan
  2. 2.Department of SurgeryKobe Rosai HospitalKobeJapan

Personalised recommendations